118 medicines are transferred out of medical insurance

1.

According to the notice, starting from January 1, 2022, 118 drugs such as amoxicillin and dicloxacillin (see the appendix for details) will be transferred out of the Zhejiang Medical Insurance List

Previously, Zhejiang Province issued a notice on the implementation of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)".

The issuance of this "Notice" is in accordance with the "Notice of the Ministry of Human Resources and Social Security of the National Medical Insurance Administration on Printing and Distributing the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" (Medical Insurance Fa [2020] No.

2.

In June 2020, the National Medical Insurance Bureau proposed in the "Notice on Doing a Good Job in Basic Medical Security for Urban and Rural Residents in 2020" that by the end of June this year, the national key monitored varieties will be removed from the catalog and 40% of the provincial supplementary varieties will be digested

In recent times, many provinces have issued the provincial supplementary medical insurance digestion list:

Qinghai: 98 drugs will be released on January 1, 2022

According to the Qinghai Provincial Medical Insurance Bureau, in 2020, a total of 129 types of nationally monitored drugs and drugs that were not recruited and used by the Qinghai Provincial Drug Procurement Platform in the previous year will be transferred.

Yunnan: 340 drugs withdrew from the medical insurance list on June 30

On July 1, 2020, the Yunnan Medical Insurance Bureau issued a notice on the “Drug Digestion Adjustment Plan for Drugs Exceeding the Scope of the National Medical Insurance Catalogue in Yunnan Province”.

It has been determined that Yunnan Province has 837 drugs beyond the scope of the national medical insurance catalogue, including 416 Western medicines and 421 Chinese patent medicines

According to the incomplete statistics of Cyber ​​Blue, many provinces have issued supplementary medical insurance digestion lists and their numbers-Beijing (224 medicines), Hebei (171 medicines), Tibet (76 medicines), Anhui (358 medicines), Tianjin (drug 79), Jilin (192 drug), Hunan (169 drug) and Jiangsu (111 drugs) and the like

According to Cyber ​​Blue, July 1, 2020, September 1, 2020, October 1, 2020, and January 1, 2021 are the main time limits for the suspension of reimbursement for some local medical insurance products

3.

At the same time, the sales of drugs that are removed from the catalog may face a substantial decline, which is undoubtedly a challenge for some pharmaceutical companies

Previously, there was a view that the smooth entry of drugs into medical insurance does not mean that they can directly enter the hospital.
Because of the restrictions on the proportion of drugs and the different hospitals’ new drug admission systems, medical representatives still need to carry out the process of entering the hospital.
Corresponding a lot of work
.

In addition, after entering the medical insurance catalog, there is a high probability that the indicators of related products will also face adjustments.
If the indicators do not increase after entering the medical insurance, then the relevant medical representative responsible for the product will achieve a certain performance within a period of next year.
The pressure may be relatively small, and it is even expected to get a good bonus
.
However, if the indicators follow the trend and more subdivision work is added to the medical insurance, the situation faced by medical representatives may not be so optimistic
.

It is worth noting that the medical insurance bureau's adjustment of the medical insurance catalog is based on market demand, cost and other reasons for reasonable deployment
.
It can be seen from the current adjustment list issued by various provinces that, in addition to the products under national key monitoring, some drugs whose clinical value is not accurate and can be better replaced; drugs that do not meet the conditions of safety, effectiveness, and economy will be taken the lead.
Being included in the cleanup list also reflects the country's support for innovative drugs
.

With the continuous update of the national medical insurance catalogue and the implementation of the drug digestion adjustment plan for the scope of the provincial medical insurance catalogue, in the future, pharmaceutical representatives and pharmaceutical companies will usher in huge opportunities and challenges
.
For pharmaceutical representatives, they should learn to actively adapt, and pharmaceutical companies should increase their investment in research and development of innovative drugs to continuously enhance their competitiveness
.

Attachment: List of related drugs